Lumida
/USPH
⌘K
US Physical Therapy Inc

US Physical Therapy Inc

USPH
$78.72USD+1.30%+1.01 today

MARKET CAP

1.2B

P/E (TTM)

154.4x

FWD P/E

DAY RANGE

$78 – $80

52W RANGE

$58
$94

AI Summary

Stalk
StalkMedium

USPH is in a Stage 2 advancing phase within a confirmed uptrend, marked by higher highs and higher lows above rising EMAs. Price is extended above the 9/20 EMA regime and approaching the 200 DMA with extreme overbought readings, suggesting an imminent pullback. We will stalk for a corrective retracement into the 9/20 EMA and 50 DMA support zones before scaling exposure, consistent with a momentum‐oriented execution style.

  • Analysts forecast 22–25% upside to $88–$102 target prices
  • 7.9% YoY revenue growth driven by outpatient rehabilitation demand
  • P/S ratio of 1.5x exceeds industry average of 1.4x
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$495.0M$553.1M$604.8M$671.3M$781.0M
YoY %+17.0%+11.7%+9.3%+11.0%+16.3%
P / Sales2.5x1.9x2.2x2.0x1.5x
EV / Sales3.0x2.5x2.5x2.5x2.0x
Gross Profit, Adj.$216.6M$553.1M$604.8M$671.3M$781.0M
YoY %+15.6%+155.4%+9.3%+11.0%+16.3%
Margin %43.7%100.0%100.0%100.0%100.0%
EV / Gross Profit6.9x2.5x2.5x2.5x2.0x
EBITDA, Adj.$82.2M$80.7M$83.7M$84.1M$109.1M
YoY %+30.7%-1.9%+3.8%+0.5%+29.7%
Margin %16.6%14.6%13.8%12.5%14.0%
EV / EBITDA18.2x17.4x18.1x20.3x14.5x
EBIT$68.0M$56.8M$50.5M$63.0M$86.7M
YoY %+29.8%-16.5%-11.1%+24.7%+37.6%
Margin %13.7%10.3%8.4%9.4%11.1%
EV / EBIT22.1x24.7x30.1x27.0x18.3x
Net Income$31.1M$29.3M$18.1M$27.7M$21.6M
YoY %-2.0%-6.0%-38.0%+52.9%-22.2%
Net Margin6.3%5.3%3.0%4.1%2.8%
EPS (GAAP)$2.41$2.25$1.28$1.84$1.42
YoY %-2.8%-6.6%-43.1%+43.8%-22.8%